BRIEF: PegBio slumps in Hong Kong trading debut
Shares of biopharmaceutical company PegBio Co. Ltd. (2565.HK) slumped in their Hong Kong trading debut on Tuesday. The stock opened at HK$13, down 6.67% from its IPO price of HK$15.60,…
BeiGene celebrates profit milestone on soaring drug sales
Buoyed by U.S. demand for its blockbuster cancer drug, the Chinese biopharma firm has delivered its first quarterly profit on a GAAP basis Key Takeaways: Global sales of the company’s…
RNA drug developer Ribo Life targets fresh funding channel
The biopharma firm has filed for a Hong Kong IPO after already completing eight financing rounds to support its research into cutting-edge nucleotide drugs Key Takeaways: As a pioneer in…
Anti-toxin provider Jiangxi Institute joins biopharma IPO rush
The company enjoys a big share of China’s anti-tetanus market but is looking to diversify into antidotes for rabies and snake bites to drive future growth Key Takeaways: The company…
WuXi group wrestles with uncertainty over pharma tariffs
Drugs services giant WuXi AppTec cashed in a stake in Wuxi XDC to soften the blow from a first round of Trump tariffs, as the pharma sector braces for another…
Investors cheer Akeso’s revenue milestone, even as it returns to the red
The drugmaker’s shares rallied after the release of its strong annual report, up by a cumulative 18% over the next three trading days Key Takeaways: Akeso’s drug sales rose 25%…
BRIEF: Hutchmed profit falls on shrinking R&D income
Hutchmed (China) Ltd. (HCM.US; 0013.HK; HCM.L), a biopharmaceutical company controlled by CK Hutchison Holdings (0001.HK), said its revenue fell 24.8% last year to $630 million, according to its annual results…